...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Effect of 1110 MBq Radioiodine in Reducing Thyroid Volume in Multinodular Goiter: A New Protocol
【24h】

Effect of 1110 MBq Radioiodine in Reducing Thyroid Volume in Multinodular Goiter: A New Protocol

机译：1110 MBq放射性碘降低多结节性甲状腺肿甲状腺体积的作用：新方案

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: There is no consensus on the optimal treatment of multinodular goiter (MNG), but in the past few years, the use of radioiodine has increased. This study’s objective was to evaluate adjuvant methimazole (MMI) therapy to increase and standardize radioiodine uptake (RAIU) with a fixed therapeutic 131I dose of 1110 MBq (30 mCi).Methods: Our study included 5 women with MNG treated with MMI, 10 - 15 mg/day for 2 to 4 months, prior to the administration of 1110 MBq 131I (30 mCi); none of the patients developed hypothyroidism during MMI therapy and had average basal TSH levels of 0.32 ± 0.39 mIU/L that increased to 2.6 ± 0.9 mIU/L (P = 0.07).Results: RAIU increased from 25.6 ± 8.7% to 49.2 ± 8.3% (P = 0.003). All patients were followed for 12 months: median thyroid volume (TV) decreased from 77.2 mL (32.9 - 124.2) to 48.8 ml (12.4 - 68.9) with an average decrease of 46.4 ± 14.8% (P = 0.01). All patients developed hypothyroidism during the first 6 months after radioiodine therapy.Conclusions: This new therapeutic protocol using MMI as adjuvant therapy is effective in increasing RAIU as well as the deleterious effects of 131I, without increasing the required dose, but leading to thyroid volume decreases similar to those reported with the use of recombinant human thyrotropin (rhTSH) or higher radioiodine doses.doi: http://dx.doi.org/10.4021/jocmr1361w
机译：背景：关于多结节性甲状腺肿（MNG）的最佳治疗方法尚无共识，但在过去几年中，放射性碘的使用有所增加。这项研究的目的是评估固定的131I治疗剂量1110 MBq（30 mCi）来提高和标准化放射性碘摄取（RAIU）的辅助治疗（MMI）方法。我们的研究包括5名接受MMI治疗的MNG妇女，10-在施用1110 MBq 131I（30 mCi）之前，每天15 mg /天，持续2到4个月;没有患者在MMI治疗期间出现甲状腺功能减退症，平均基础TSH水平为0.32±0.39 mIU / L，升高至2.6±0.9 mIU / L（P = 0.07）。结果：RAIU从25.6±8.7％增至49.2±8.3 ％（P = 0.003）。所有患者均接受了12个月的随访：甲状腺中位数（TV）从77.2 mL（32.9-124.2）降至48.8 ml（12.4-68.9），平均降低46.4±14.8％（P = 0.01）。所有患者在放射碘治疗后的前6个月均出现甲状腺功能减退。结论：这种新的使用MMI作为辅助疗法的治疗方案可有效增加RAIU以及131I的有害作用，而无需增加所需剂量，但会导致甲状腺体积减少与使用重组人促甲状腺激素（rhTSH）或更高剂量的放射性碘报道的报道相似。doi：http://dx.doi.org/10.4021/jocmr1361w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号